The 2 Worst Performing Chinese Electric Vehicle Stocks YTD

: NIO | NIO Inc. ADR News, Ratings, and Charts

NIO – The Chinese electric vehicle (EV) industry saw a rocketing rally last year. But the absence of requisite financial strength and product pipelines are lately causing a pullback by many of these stocks. NIO Limited (NIO) and XPeng Inc. (XPEV) are two of the worst performing stocks in this space so far this year. And, given the weakness in their financials, we think they are best avoided now.

China-based electric vehicles (EV) manufacturers account for most global EV deliveries. In fact, the 1.3 million EVs sold in China in 2020 represented 41% of global EV sales. However, the EV boom has given rise to many EV start-ups in the country that have yet to develop production capacity to capitalize on the growing demand. And existing players are facing stiff competition in maintaining  their market share.

As a result, investors have become concerned about  the current valuations of Chinese EV stocks. And the stocks that have skyrocketed in the absence of sufficient fundamental strength based solely on investors’ optimism have been experiencing  a major sell-off this year.

Furthermore, a current global semiconductor shortage has led many automakers to halt their production. This represents another investor concern. NIO Limited (NIO) and XPeng Inc. (XPEV) have retreated significantly this year, and it’s a trend that may not reverse anytime soon. So, we think it  wise to avoid these two stocks now.

Click here to checkout our Electric Vehicle Industry Report for 2021

NIO Limited (NIO)

Based in China, NIO designs, jointly manufactures, and sells smart premium electric vehicles, driving innovations in next-generation technologies in connectivity, autonomous driving, and artificial intelligence. The company provides users with comprehensive and convenient power solutions including Battery as a Service (BaaS), NIO Pilot and NIO Autonomous Driving (NAD), Autonomous Driving as a Service (ADaaS) and other user-centric services.

On March 26, NIO decided to  temporarily suspend its  vehicle production  in its  JAC-NIO manufacturing plant in Hefei for several working days due to a semiconductor shortage. The overall semiconductor supply constraint   impacted the company’s production this month.  Consequently,  NIO has also lowered its vehicle delivery outlook for the first quarter.

NIO’s total revenues have  increased 46.7% sequentially to $1.02 billion in the fourth quarter ended December 31. However, its top-line growth has not  translated into profits. Its net loss has increased 32.4% from the previous quarter to $212.82 million, while its loss per share has risen 7.1% to $0.16.

Analysts expect NIO to report a loss per share of $0.15 in the current quarter ending March 31, 2021. The stock has lost 23% year-to-date and is currently trading at 11 times its sales, 776.8% higher than the industry average  1.25x.

NIO’s POWR Ratings are consistent with this bleak outlook. The stock has a D overall rating,  which equates to Sell in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.

NIO has a D grade for Sentiment, Value, and Quality. It is currently ranked #81 of 84 stocks in the D-rated China industry.

In total, we rate NIO on eight different levels. Beyond what we’ve stated above, we have also  given NIO grades for Momentum, Stability, and Growth. Get all of NIO’s ratings here.

XPeng Inc. (XPEV)

XPEV is a Chinese smart electric vehicle company that designs, develops, manufactures, and markets smart electric vehicles. The company’s primary products are a type of sport utility vehicle named G3 and four-door sports sedan named the P7. It also provides vehicle leasing, bank loans, and auto insurance services.

This month , XPEV’s subsidiary in China entered a strategic cooperation agreement with Guangdong Yuecai Investment Holdings Co., Ltd. Pursuant to the agreement, Yuecai will invest a total of RMB500 million in XPEV’s subsidiary in China to accelerate the company’s business expansion.

The company’s revenues in the fourth quarter (ended December 31, 2020) were $436.99 million, surging 345.5% year-over-year. However, XPEV is still unprofitable and reported a loss of $171.83 million.

Analysts expect XPEV to report a loss per share of $0.15 in the current quarter, ending March 31. The stock has lost 21% year-to-date and is currently trading 12.21 times its sales, 875.6% higher than the industry average.

XPEV’s poor prospects are apparent in its POWR Ratings also. The stock has an overall D rating,  equating to Sell in our proprietary rating system. XPEV also has a D grade for Quality, Stability, and Value. In the Auto & Vehicle Manufacturers industry, the stock is ranked #44 of 51 stocks.

Click here to see the additional POWR Ratings for XPEV (Momentum, Growth, and Sentiment).

The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.

Click here to checkout our Electric Vehicle Industry Report for 2021

Want More Great Investing Ideas?

“MUST OWN” Growth Stocks for 2021

How to Ride the NEW Stock Bubble?

5 WINNING Stocks Chart Patterns

Unlock the POWR in Your Portfolio!


NIO shares were trading at $38.44 per share on Wednesday afternoon, up $0.89 (+2.37%). Year-to-date, NIO has declined -21.13%, versus a 6.76% rise in the benchmark S&P 500 index during the same period.


About the Author: Rishab Dugar


Rishab is a financial journalist and investment analyst. His investment approach is to focus on quality stocks, trading at low prices, with business models that he readily understands. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
NIOGet RatingGet RatingGet Rating
XPEVGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

How to Beat the Market the Rest of the Year?

The easy gains that came at the start of this new bull market are fading away fast. In fact the stock market (SPY) has become quite volatile with gains harder to come by. Gladly there are solutions as will be shared in this commentary to get you on the right path to outperform the market through the end of 2021 and beyond. Read the rest below...

:  |  News, Ratings, and Charts

2022 Stock Market Outlook

The stock market (SPY) has continued on a bullish path in 2021. Will that continue in 2022? And what could happen to awaken the bear market from hibernation? 40 year investment veteran Steve Reitmeister explores this and more in this early edition of his 2022 Stock Market Outlook. Read on for full details below...

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

:  |  News, Ratings, and Charts

3 Value Stocks to Buy While You Still Can

After outperforming from last fall into the spring, value stocks have been overtaken by growth stocks, but that is expected to change as the economic recovery continues. So, now is the time to start putting your money to work in undervalued companies that offer the potential for strong returns such as Gilead Sciences Inc. (GILD), HP Inc. (HPQ), and CNH Industrial N.V. (CNHI).

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

Read More Stories

More NIO Inc. ADR (NIO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NIO News